Skip to main
HIMS

HIMS Stock Forecast & Price Target

HIMS Analyst Ratings

Based on 13 analyst ratings
Buy
Strong Buy 23%
Buy 15%
Hold 62%
Sell 0%
Strong Sell 0%

Bulls say

Hims & Hers Health is currently facing some short-term challenges with lower than expected results and a lowered outlook for FY26, but their strong partnership with Novo is expected to drive future growth. With a raised price target of $35 and a Buy rating, the company has potential for a $1 billion revenue and increased market opportunity. However, they must carefully navigate competition and maintain a favorable LTV to CAC ratio in the telehealth market while also addressing potential risks from regulations and changes in their business model. The recent collaboration with Novo to offer FDA approved medications should help mitigate previous legal concerns and support the company's overall growth.

Bears say

Hims & Hers Health is facing multiple challenges including slow revenue growth, declining margins, and increased regulatory scrutiny. Compounding pharmacies, which are key to Hims & Hers' business model, face potential tighter regulations that could impact the company's ability to offer customized medications. In addition, higher costs associated with shifting to branded drugs and potential data breaches could hurt Hims & Hers' profitability and reputation, while increasing volatility in the stock price. These challenges outweigh potential growth opportunities in the weight loss market and international expansion, leading to a negative outlook for the company's stock.

HIMS has been analyzed by 13 analysts, with a consensus rating of Buy. 23% of analysts recommend a Strong Buy, 15% recommend Buy, 62% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hims & Hers Health and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hims & Hers Health (HIMS) Forecast

Analysts have given HIMS a Buy based on their latest research and market trends.

According to 13 analysts, HIMS has a Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.77, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.77, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hims & Hers Health (HIMS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.